GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab to 12 university partnerships

GlucoTrack’s wholly owned subsidiary Lōkahi Therapeutics expanded its ai² Futures Lab pipeline-sourcing program focused on shelved or under-prioritized drug assets.

• First-year output: more than 45 late-stage therapeutic opportunities screened on a budget of about USD 33,000.
• Five opportunities moved into active company discussions; evaluated assets represented more than USD 500 million in prior biopharma investment.
• Program scale-up targets 12 university collaborations for the 2026-2027 academic year, up from six, with 100% retention of inaugural partners.